Study Type

Cognitive Impairment & Alzheimer's Disease

Study Purpose

The purpose of this research study is to test the safety and tolerability of the investigational drug MK-8931 in the treatment of subjects with Mild Cognitive Impairment (aMCI) due to Alzheimer's Disease (AD).

About the Study

MK-8931 is a new drug that is being studied by Merck to see if it has any effect in treating Alzheimer's disease.

Study Design

Number of visits:

  • 1 Screening visit
  • 11 Clinic visits over a two year period
  • ~8 telephone calls

Study procedures:

  • Height, weight, vitals, physical and neurological exam
  • MRI
  • PET scan
  • Electrocardiogram (ECG)
  • Urinalysis and blood draws
  • Questionnaires and interviews
  • Eye exam

Eligible participants will be assigned by chance to one of the following treatment groups:

  • MK-8931 12mg once a day
  • MK-8931 40mg once a day
  • Placebo once a day
Participants will take the study drug once per day by mouth. All study procedures and medications will be provided at no cost to participants.

Study Qualifications

  • Age: 50-85
  • You meet the criteria for a diagnosis of probable Alzheimer’s Disease as determined by a PET scan at the screening visit
  • You have a clear history of cognitive and functional decline over at least one year that is either documented in medical records or documented by report from an informant who knows you well

Study Duration

26 months


Earn up to $975 for participation.

Study Contact

If you are interested in volunteering for this trial, call the Institute for Dementia Research and Prevention at 225-763-2973 or email dementia@pbrc.edu.


English Calculation
Enter Your Weight: 
Enter Your Height: 
 ft.  in.
Your BMI: